Literature DB >> 22821645

Acromegalic patients lost to follow-up: a pilot study.

Leandro Kasuki1, Nelma Verônica Marques, Maria José Braga La Nuez, Vera Lucia Gomes Leal, Renata N Chinen, Mônica R Gadelha.   

Abstract

Approximately 50 % of all acromegalic patients will require lifelong medical treatment to normalize mortality rates and reduce morbidity. Thus, adherence to therapy is essential to achieve treatment goals. To date, no study has evaluated the frequency and reasons for loss to follow-up in the acromegalic population. The current study aimed at evaluating the frequency of acromegalic patient loss to follow-up in three reference centers and the reasons responsible for their low compliance with treatment. All of the files for the acromegalic patients in the three centers were reviewed. Those patients, who had not followed up with the hospital for more than a year, were contacted via phone and/or mail and invited to participate. Patients who agreed to participate were interviewed, and blood samples were collected. A total of 239 files were reviewed; from these 42 patients (17.6 %) were identified who were lost to follow-up. It was possible to contact 27 of these patients, 10 of whom did not attend the appointments for more than one time and 17 of whom agreed to participate in the study. Fifteen of these 17 patients had active disease (88.2 %), and all of the patients restarted treatment in the original centers. The main reason for loss to follow-up was an absence of symptoms. High-quality follow-up is important in acromegaly to successfully achieve the aims of the treatment. An active search for patients may allow the resumption of treatment in a significant proportion of these cases, contributing to reduced morbidity and mortality in this patient population.

Entities:  

Mesh:

Year:  2013        PMID: 22821645     DOI: 10.1007/s11102-012-0412-x

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  28 in total

Review 1.  Combination treatment with somatostatin analogues and pegvisomant in acromegaly.

Authors:  S J C M M Neggers; A J van der Lely
Journal:  Growth Horm IGF Res       Date:  2011-04-16       Impact factor: 2.372

2.  Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

Authors:  Pamela U Freda; Laurence Katznelson; Aart Jan van der Lely; Carlos M Reyes; Shouhao Zhao; Daniel Rabinowitz
Journal:  J Clin Endocrinol Metab       Date:  2005-05-10       Impact factor: 5.958

3.  Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.

Authors:  Pamela U Freda; Carlos M Reyes; Abu T Nuruzzaman; Robert E Sundeen; Alexander G Khandji; Kalmon D Post
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

4.  Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses.

Authors:  Deborah T Gold
Journal:  J Manag Care Pharm       Date:  2006-07

5.  Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.

Authors:  Lucio Vilar; Monalisa F Azevedo; Luciana Ansaneli Naves; Luiz Augusto Casulari; José Luciano Albuquerque; Renan M Montenegro; Renan M Montenegro; Patricia Figueiredo; Gilvan C Nascimento; Manuel S Faria
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

Review 6.  Place of cabergoline in acromegaly: a meta-analysis.

Authors:  Laure Sandret; Patrick Maison; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

7.  Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?

Authors:  Claudia Ramírez; Guadalupe Vargas; Baldomero González; Ashley Grossman; Julia Rábago; Ernesto Sosa; Ana Laura Espinosa-de-Los-Monteros; Moisés Mercado
Journal:  Eur J Endocrinol       Date:  2011-10-12       Impact factor: 6.664

8.  AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects.

Authors:  Marie Bex; Roger Abs; Guy T'Sjoen; Jean Mockel; Brigitte Velkeniers; Katja Muermans; Dominique Maiter
Journal:  Eur J Endocrinol       Date:  2007-10       Impact factor: 6.664

Review 9.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

Review 10.  Improving patient compliance: a major goal in the management of hypertension.

Authors:  Joel M Neutel; David H G Smith
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Mar-Apr       Impact factor: 3.738

View more
  9 in total

1.  The acromegalic spine: fractures, deformities and spinopelvic balance.

Authors:  Bruno de Azevedo Oliveira; Bruna Araujo; Tainá Mafalda Dos Santos; Bárbara Roberta Ongaratti; Carolina Garcia Soares Leães Rech; Nelson Pires Ferreira; Júlia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

2.  A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.

Authors:  Roberto Salvatori; Murray B Gordon; Whitney W Woodmansee; Adriana G Ioachimescu; Don W Carver; Beloo Mirakhur; David Cox; Mark E Molitch
Journal:  Pituitary       Date:  2017-12       Impact factor: 4.107

3.  Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients.

Authors:  Adriana G Ioachimescu; Talin Handa; Neevi Goswami; Adlai L Pappy; Emir Veledar; Nelson M Oyesiku
Journal:  Endocrine       Date:  2019-11-01       Impact factor: 3.633

Review 4.  A practical approach to acromegaly management in Latin America.

Authors:  Marcello D Bronstein; Oscar D Bruno; Alin Abreu; Ruth Mangupli; Moisés Mercado
Journal:  Pituitary       Date:  2014-01       Impact factor: 4.107

5.  Communication practices and awareness of resources for acromegaly patients among endocrinologists.

Authors:  Susan Polanco-Briceno; Daniel Glass; Cindy Plunkett
Journal:  Patient Prefer Adherence       Date:  2016-12-14       Impact factor: 2.711

Review 6.  Novel therapies for acromegaly.

Authors:  Bernardo Maia; Leandro Kasuki; Mônica R Gadelha
Journal:  Endocr Connect       Date:  2020-12       Impact factor: 3.335

7.  The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences.

Authors:  Cynthia Plunkett; Ariel L Barkan
Journal:  Patient Prefer Adherence       Date:  2015-07-30       Impact factor: 2.711

Review 8.  Need for improved monitoring in patients with acromegaly.

Authors:  Julie M Silverstein
Journal:  Endocr Connect       Date:  2015-09-17       Impact factor: 3.335

9.  Do We Need a Specific Guideline for Assessment and Improvement of Acromegaly Patients Adherence?

Authors:  Maria Kamusheva; Alexina Parvanova; Yanitsa Rusenova; Silvia Vandeva; Atanaska Elenkova
Journal:  Front Public Health       Date:  2021-07-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.